Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases

doi:10.5217/ir.2019.09155

Review

. 2020 Jan;18(1):18-33.

doi: 10.5217/ir.2019.09155. Epub 2020 Jan 30.

Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases

Affiliations

¹ Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
² Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
³ Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
⁴ Center for Preventive Medicine and Public Health, Seoul National University Bundang Hospital, Seongnam, Korea.
⁵ Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
⁶ Department of Internal Medicine, Institute of Gastroenterology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
⁷ Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.
⁸ Division of Gastroenterology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
⁹ Division of Gastroenterology, Department of Medicine, Soonchunhyang University College of Medicine, Cheonan, Korea.
¹⁰ Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

PMID: 32013312
PMCID: PMC7000641
DOI: 10.5217/ir.2019.09155

Review

Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases

Soo-Kyung Park et al. Intest Res. 2020 Jan.

. 2020 Jan;18(1):18-33.

doi: 10.5217/ir.2019.09155. Epub 2020 Jan 30.

Authors

Affiliations

¹ Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
² Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
³ Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
⁴ Center for Preventive Medicine and Public Health, Seoul National University Bundang Hospital, Seongnam, Korea.
⁵ Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
⁶ Department of Internal Medicine, Institute of Gastroenterology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
⁷ Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.
⁸ Division of Gastroenterology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
⁹ Division of Gastroenterology, Department of Medicine, Soonchunhyang University College of Medicine, Cheonan, Korea.
¹⁰ Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

PMID: 32013312
PMCID: PMC7000641
DOI: 10.5217/ir.2019.09155

Abstract

The treatment of inflammatory bowel disease (IBD) has been revolutionized for the last 10 years by the increasing use of immunomodulators and biologics. With immunosuppression of this kind, opportunistic infection is an important safety concern for patients with IBD. In particular, viral hepatitis is determined by the interaction between the virus and the host's immunity, and the risk of reactivation increases if immunity is compromised by immunosuppression therapy. Parts of Asia, including Korea, still show intermediate endemicity for the hepatitis A virus and hepatitis B virus compared with the United States and Western Europe. Thus, members of IBD research group of the Korean Association for the Study of Intestinal Diseases have produced a guideline on the prevention and management of viral hepatitis in IBD.

Keywords: Inflammatory bowel disease; Prevention; Vaccination; Viral hepatitis.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

Cited by

Current Status of Opportunistic Infection in Inflammatory Bowel Disease Patients in Asia: A Questionnaire-Based Multicenter Study.
Yang H, Ran Z, Jin M, Qian JM. Yang H, et al. Gut Liver. 2022 Sep 15;16(5):726-735. doi: 10.5009/gnl210217. Epub 2022 May 25. Gut Liver. 2022. PMID: 35611664 Free PMC article.
Do We Have an Opportunity to Avoid Opportunistic Infections in Asian Patients with Inflammatory Bowel Disease?
Park S, Park SH. Park S, et al. Gut Liver. 2022 Sep 15;16(5):663-664. doi: 10.5009/gnl220364. Gut Liver. 2022. PMID: 36104208 Free PMC article. No abstract available.
Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease.
Lee JM, Wei SC, Lee KM, Ye BD, Mao R, Kim HS, Park SJ, Park SH, Oh EH, Im JP, Jang BI, Kim DB, Takeuchi K. Lee JM, et al. Gut Liver. 2022 May 15;16(3):396-403. doi: 10.5009/gnl210081. Gut Liver. 2022. PMID: 34593670 Free PMC article.
Viral infections in inflammatory bowel disease: Tips and tricks for correct management.
Craviotto V, Furfaro F, Loy L, Zilli A, Peyrin-Biroulet L, Fiorino G, Danese S, Allocca M. Craviotto V, et al. World J Gastroenterol. 2021 Jul 21;27(27):4276-4297. doi: 10.3748/wjg.v27.i27.4276. World J Gastroenterol. 2021. PMID: 34366605 Free PMC article. Review.
The impact of medication belief on adherence to infliximab in patients with Crohn's disease.
Li S, Ma Y, Sun H, Ni Z, Hu S, Chen Y, Lan M. Li S, et al. Front Pharmacol. 2023 Aug 14;14:1185026. doi: 10.3389/fphar.2023.1185026. eCollection 2023. Front Pharmacol. 2023. PMID: 37645443 Free PMC article.

See all "Cited by" articles

References

1. Ooi CJ, Hilmi I, Banerjee R, et al. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia. Intest Res. 2019;17:285–310. - PMC - PubMed
1. Rahier JF, Magro F, Abreu C, et al. Second European evidencebased consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8:443–468. - PubMed
1. Korean Association for the Study of the Liver KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol. 2016;22:18–75. - PMC - PubMed
1. Ye BD, Travis S. Improving the quality of care for inflammatory bowel disease. Intest Res. 2019;17:45–53. - PMC - PubMed
1. Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017;112:241–258. - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources

[1] Ooi CJ, Hilmi I, Banerjee R, et al. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia. Intest Res. 2019;17:285–310. - PMC - PubMed

[2] Ooi CJ, Hilmi I, Banerjee R, et al. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia. Intest Res. 2019;17:285–310. - PMC - PubMed

[3] Rahier JF, Magro F, Abreu C, et al. Second European evidencebased consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8:443–468. - PubMed

[4] Rahier JF, Magro F, Abreu C, et al. Second European evidencebased consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8:443–468. - PubMed

[5] Korean Association for the Study of the Liver KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol. 2016;22:18–75. - PMC - PubMed

[6] Korean Association for the Study of the Liver KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol. 2016;22:18–75. - PMC - PubMed

[7] Ye BD, Travis S. Improving the quality of care for inflammatory bowel disease. Intest Res. 2019;17:45–53. - PMC - PubMed

[8] Ye BD, Travis S. Improving the quality of care for inflammatory bowel disease. Intest Res. 2019;17:45–53. - PMC - PubMed

[9] Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017;112:241–258. - PubMed

[10] Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017;112:241–258. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases

Affiliations

Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

Related information

LinkOut - more resources

Full Text Sources